



Barely two weeks after the British
press went bananas over cancer
research published in the Proceedings
of the National Academy of Sciences, the
US press took a turn. This time,
though, the breathtaking results
were published in that prestigious
medical journal, the New York Times.
It’s odd that the media went
berserk over this article. The
substance was not new — many
reporters had written articles about
the subject over the years. Dr Judah
Folkman at Harvard Medical School
has been working on two natural
factors that cut off blood supply to
tumors, angiostatin and endostatin.
He reported in November in Nature
that these anti-angiogenesis factors
work surprisingly well in shrinking
tumors implanted on mice. The
Times’ suburban rival, Newsday,
published an article in November.
And back in January, the Times itself
ran a long, thoughtful profile of
Folkman and his work.
The ‘news’ that created a tidal-
wave of follow-up stories was this: the
New York Times article on Sunday,
May 3rd had hot quotes and great
play. Gina Kolata quoted James
Watson saying, “Judah is going to cure
cancer in two years.” The Times report
also declared that the National Cancer
Institute (NCI) had made the drugs
their top priority. And to top it off, the
story ran on page one, above the fold,
giving the Times’ own influential
imprimatur to the report. Of course,
the Times dutifully reported that the
breathtaking results were only in mice
— human trials haven’t even started
— and many caveats were responsibly
placed high up in the story. But the
words that resonated were simply
these: cancer and cure.
The first wave of stories mostly
tried to match the Times. The banner
headline in USA Today the next day
was “Cancer War May Have New
Weapon.” The story made it seem
simple: “Mounting evidence suggests
that doctors may be able to wipe out
cancer by cutting off the tumor’s
blood supply.” Sounds like a cure,
even though Folkman himself was
quoted saying, “Will this work in
humans? No one knows.” The story
played all day Monday on CNN and
led national TV newscasts that night.
Other reporters who tried to resist
the story for its obvious hype were
sucked into the vortex that the Times
story itself created. First to go were
the business reporters, after
EntreMed, the company licensed to
produce angiostatin and endostatin,
saw its stock value quadruple in a
matter of hours, on the basis of the
Times story. Next, the more cautious
science reporters were dragooned into
doing the story after editors decided
that it simply couldn’t be ignored.
EntreMed’s stock value quadrupled
on the basis of the Times story
Here’s how Rick Weiss at the
Washington Post put it: “Two
experimental cancer drugs whose
ability to shrink tumors in mice
triggered a stampede of interest
earlier this week are unlikely to have
a huge effect on human cancer if
experience with similar drugs is an
indication, several experts said
yesterday.” Many reports mentioned
the checkered histories of interferon
and interleukin. The Boston Globe’s
sober story ran a headline “Caution is
Urged Over New Drugs.” The report
noted that Folkman canceled a
planned lecture after the story broke
because he didn’t want to be accosted
by photographers and TV cameras.
The Times itself published a more
cautionary story as momentum
swelled over the original report, as
well as a letter from James Watson
denying the two-years-to-a-cure
quote — though Watson said he had
spoken to Kolata at a dinner party
and he reiterated that he’s very
enthusiastic about the drugs. Next
came a correction in the Times. Dr
Klausner at the NCI did not say that
the drugs are the institute’s top
priority, though, splitting a semantic
hair, Klausner did say that nothing at
the institute has a higher priority.
Soon the news was not about the
science at all — but about the Times’
story. Newsday, for example, noted
“some science journalists are now
complaining that the story was old
news, overplayed, and that the
subsequent frenzy of stories cruelly
gave false hope to those with the
disease.” The article quoted
Shannon Brownlee at US News &
World Report saying “I would never
say to my editors, ‘Let’s put this one
on the cover’.” But that’s where the
story of the story ended up. The
spectacle became the subject of
cover stories not just for US News,
but for Time and Newsweek as well.
Headlines managed to work in
references to both hope and hype.
And as if there weren’t enough
angles already, the Los Angeles Times
reported, “several publishing houses
confirmed Tuesday that they had
received copies of a book proposal
about the alleged cancer cure from…
an agent representing Gina Kolata.”
This revelation sparked a new spate
of articles, including one in the
Baltimore Sun, asking whether it’s
ethical for a reporter in Kolata’s
position to cash in on the intense
public interest she created. The New
York Times ran an article on this
subject, as well, noting that Kolata
had withdrawn her proposal.
But across the East River, a
colleague of hers is no doubt smiling
broadly. Bob Cooke at Newsday had
been circulating a book proposal on
Folkman’s work, and after the Kolata
story broke, it didn’t take long for a
publisher to bite. The reported
advance: one million dollars.
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